What are the most common mistakes with IGF-1 LR3?
The most common IGF-1 LR3 mistakes are running it longer than 4 weeks; dosing fasted (hypoglycemia); stacking with insulin or insulin-sensitizers without monitoring. Most issues people run into come down to protocol and expectations, not the compound itself. Going in informed matters here because human evidence for IGF-1 LR3 is limited.
Common IGF-1 LR3 mistakes
- Running it longer than 4 weeks
- Dosing fasted (hypoglycemia)
- Stacking with insulin or insulin-sensitizers without monitoring
Bloodwork worth tracking
- Fasting glucose every 2 weeks
- IGF-1 baseline + at week 4
References
- IGF-I and its analogs in clinical use — Clemmons DR, Endocrinol Metab Clin North Am, 2012
- Detection of His-tagged Long-R3-IGF-I in a black market product — Kohler M, Thomas A, Walpurgis K, et al., Growth Hormone & IGF Research, 2010
- Site-specific fluorescent derivatization and liquid chromatographic-mass spectrometric characterization of long R(3) IGF-I for bioanalytical applications — Harvey MD, Banks PR, Journal of Chromatography B, 2003
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on IGF-1 LR3
Last updated 2026-06-15.